Although its expression correlates with poor prognosis in colorectal cancer (30) and drug resistance in colon cancer (31), GRM4 agonists can inhibit the proliferation of non-CNS-origin cultured cancer cells, such as bladder cancer cells (32). The gene discussed is GRM4; the disease is colonic neoplasm.